ENDOCYTE - Small and Powerful Targeted Therapy!
Endocyte’s (ECYT) SMDC technology platform and drug pipeline caught investor’s attention when Merck paid total $1b + 50/50 profit sharing in US + royalty payment on ex. US to its key drug Vintafolide. ECYT expects a response to the 120-day questions submission by mid year based on which Merck will make a no/go decision on the MAA. While the data looks promising in FR+ve pts for PFS, no OS benefit has been observed in PhII. The PhIII trial is more stringent and the odds of success are high. Attractive technology platform- SMDC has broad application and offers advantage over antibody drug conjugate technologies. ECYT has a robust cash position and presents..…..For more detail, please read our initiation report released on 19th April, 2013 on ECYT titled “Small and Powerful Targeted Therapy!
